Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Working Capital Changes (2021 - 2025)

Aligos Therapeutics' Other Working Capital Changes history spans 5 years, with the latest figure at -$113000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 94.43% year-over-year to -$113000.0; the TTM value through Dec 2025 reached -$96000.0, up 96.42%, while the annual FY2025 figure was -$96000.0, 96.42% up from the prior year.
  • Other Working Capital Changes reached -$113000.0 in Q4 2025 per ALGS's latest filing, up from -$411000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $12.4 million in Q2 2022 to a low of -$10.1 million in Q3 2022.
  • Average Other Working Capital Changes over 5 years is -$569300.0, with a median of -$389000.0 recorded in 2021.
  • The largest YoY upside for Other Working Capital Changes was 993.28% in 2022 against a maximum downside of 297.8% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at -$367000.0 in 2021, then tumbled by 32.15% to -$485000.0 in 2022, then skyrocketed by 314.43% to $1.0 million in 2023, then plummeted by 294.9% to -$2.0 million in 2024, then soared by 94.43% to -$113000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Other Working Capital Changes are -$113000.0 (Q4 2025), -$411000.0 (Q3 2025), and $579000.0 (Q2 2025).